Illustrative image – not actual.Mumbai-based Sun Pharmaceutical Industries has received approval from the US food and drug administration (USFDA) to sell generic version of Doxil, a scarce anti-cancer drug.
Doxil’s chemical name doxorubicin hydrochloride liposome injection is currently on the USFDA’s drug shortage list. This medicine approval is expected to further boost export earnings of Sun Pharma, which has significant presence in the US. Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.
Source: Financial Chronicle
